Gland Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Gland Pharma's recent performance and strategic initiatives underscore a robust growth trajectory, particularly in its US CDMO business, which management projects will drive a 20% revenue CAGR over the next four years. Key developments include the successful launch of 31 products in FY26, including Liraglutide, and the ramp-up of the Fontenay facility, enhancing capacity significantly. These factors support Vista's forecast of accelerating revenue growth and improving margins, aligning with the company's focus on high-value injectables and complex drug-device combinations. However, analysts express caution regarding the feasibility of the long-term growth targets, particularly due to potential supply chain disruptions and the integration challenges associated with the Cenexi acquisition. The industry context remains favorable, with increasing demand for contract development and manufacturing services, although competitive pressures may impact pricing power. Over the next 12-24 months, Gland Pharma's key opportunities lie in expanding its product pipeline and leveraging its CDMO capabilities, while watchpoints include execution risks related to new contracts and market dynamics in emerging regions
Why We Like This Stock
- Management's target of a 20% revenue CAGR over the next four years is supported by a strong pipeline of complex injectables and new CDMO partnerships
- The ramp-up of the Fontenay facility is set to significantly enhance production capacity, positioning Gland Pharma to meet increasing market demand
- The company's focus on high-value therapeutic areas, such as GLP-1 therapies, aligns with global healthcare trends, providing a solid foundation for long-term growth
Things To Watch Out For
- Analysts express caution regarding the feasibility of the long-term CAGR guidance due to potential supply chain disruptions and integration challenges with Cenexi
- Competitive pressures in the industry may impact pricing power, affecting overall profitability
- Execution risks related to the 24-month technology transfer timeline for new contracts could hinder anticipated growth
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 5,665 | 5,616 | 6,431 | 7,050 | 8,293 |
| Profit Before Tax (Cr.) | 1,132 | 1,062 | 1,489 | 2,134 | 2,302 |
| PBT Margin | 20.0% | 18.9% | 2315.3% | 30.3% | 27.8% |
| Net Profit (Cr.) | 783 | 691 | 1,023 | 1,463 | 1,579 |
| Earnings Per Share | 47.5 | 41.9 | 62.0 | 88.7 | 95.7 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Elara Capital | ► Accumulate | 2,956 | 11-Aug-2026 |
| Goldman Sachs | ▼ Sell | 2,125 | 11-Aug-2026 |
| ICICI Securities | ▲ Buy | 2,365 | 18-May-2026 |
| Jeffries | ▲ Buy | 3,350 | 11-Aug-2026 |
| Kotak Securities | ► Add | 2,625 | 27-Jul-2026 |
| Motilal Oswal | ▲ Buy | 3,080 | 11-Aug-2026 |
Company Overview
Show Company Profile
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.